Accuracy validation of adjuvant! online in Taiwanese breast cancer patients - a 10-year analysis by Kuo Yao-Lung et al.
Kuo et al. BMC Medical Informatics and Decision Making 2012, 12:108
http://www.biomedcentral.com/1472-6947/12/108RESEARCH ARTICLE Open AccessAccuracy validation of adjuvant! online in
Taiwanese breast cancer patients - a 10-year
analysis
Kuo Yao-Lung1, Chen Dar-Ren2* and Chang Tsai-Wang3*Abstract
Background: Adjuvant! Online (www.adjuvantonline.com) is an Internet-based software program that allows
clinicians to make predictions about the benefits of adjuvant therapy and 10-year survival probability for early-stage
breast cancer patients. This model has been validated in Western countries such as the United States, United
Kingdom, Canada, Germany, and Holland. The aim of our study was to investigate the performance and accuracy of
Adjuvant! Online in a cohort of Taiwanese breast cancer patients.
Methods: Data on the prognostic factors and clinical outcomes of 559 breast cancer patients diagnosed at the
National Cheng Kung University Hospital in Tainan between 1992 and 2001 were enrolled in the study.
Comprehensive demographic, clinical outcome data, and adjuvant treatment data were entered into the Adjuvant!
Online program. The outcome prediction at 10 years was compared with the observed and predicted outcomes
using Adjuvant! Online.
Results: Comparison between low- and high-risk breast cancer patient subgroups showed significant differences in
tumor grading, tumor size, and lymph node status (p< 0.0001). The mean 10-year predicted death probability in
559 patients was 19.44%, and the observed death probability was 15.56%. Comparison with the Adjuvant!
Online-predicted breast cancer-specific survival (BCSS) showed significant differences in the whole cohort
(p< 0.001). In the low-risk subgroup, the predicted and observed outcomes did not differ significantly (3.69% and
3.85%, respectively). In high-risk patients, Adjuvant! Online overestimated breast cancer-specific survival (p= 0.016);
the predicted and observed outcomes were 21.99% and 17.46%, respectively.
Conclusions: Adjuvant! Online accurately predicted 10-year outcomes and assisted in decision making about
adjuvant treatment in low-risk breast cancer patients in our study, although the results were less accurate in the
high-risk subgroup. Development of a prognostic program based on a national database should be considered,
especially for high-risk breast cancer patients in Taiwan.
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Breast cancer treatments are based mainly on international
guideline recommendations (e.g., the National Comprehen-
sive cancer Network (NCCN) guidelines or St. Gallen con-
sensus) [1-3]. Improvements in the efficacy of adjuvant
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reproduction in any medium, provided the orbreast cancer [4]. Adjuvant drug therapy can extend sur-
vival in breast cancer patients, although the balance between
risks and benefits must be considered. The decision to pre-
scribe adjuvant systemic therapy for early breast cancer
patients is complex and requires consideration of conditions
such as the patient’s and tumor characteristics, treatment ef-
fectiveness, and clinician and patient preferences. However,
inaccurate outcome predictors can lead to the over- or
undertreatment of patients. Recently, several statistical mod-
els or programs have been developed to predict outcomes
for early breast cancer patients [5-10]. These programs can. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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individualized treatment strategy based on a number of
prognostic factors.
Adjuvant! Online is a Web-based, open-access com-
puter program that predicts patient outcome at 10 years
in breast cancer patients [10]. The development of the
program is based on information from the Surveillance,
Epidemiology, and End Results (SEER) registry. The
SEER registry includes data for about 10% of breast can-
cer patients in the USA. The program analyzed the out-
come of 10-year survival probabilities, risk of relapse,
and survival using patient information and tumor char-
acteristics such as age, tumor size, tumor grade, estrogen
receptor (ER) status, and lymph node status [11].
Adjuvant! Online was validated successfully by Oli-
votto and colleagues in a population-based series of
4083 early-stage breast cancer patients in Canada [12].
They concluded that the Adjuvant! Online program ac-
curately predicted the observed breast cancer-related
death outcome within 2% in the whole study population.
However, Asian populations might differ from those in
the USA or Canada, and the accuracy of Adjuvant! On-
line in predicting outcomes in the Asian, particularly the
Taiwanese population is unknown.
The aims of our study were to validate the accuracy of
Adjuvant! Online, to predict outcomes in different pa-
tient groups, and to distinguish individuals who will
need different prediction methods in a cohort of Taiwan-
ese patients with breast cancer treated at a multidiscip-
linary tumor board in a university hospital.
Methods
Between January 1, 1992, and December 31, 2001, 652
breast cancer patients were diagnosed and treated at Na-
tional Cheng Kung University Hospital (NCKUH) in Tai-
nan, Taiwan. The final cohort involved in the subset of
559 patients fulfilled the following criterion: follow-up
period > 10 years or death due to breast cancer within
10 years from the diagnosed date. Ninety-three patients
were excluded because of loss to follow-up or death
from other causes. In all analyzed cases, 472 patients
whose follow-up period was > 10 years were classified as
“survived” (84.44%), and the other 87 patients who died
of breast cancer within 10 years were classified as “died”
(15.56%). Those who died of breast cancer beyond the
10-year follow-up were also classified as survived. Ethical
approval was provided by the Human Experiment and
Ethics Committee of the National Cheng Kung Univer-
sity Hospital (A-ER-101-013).
The demographic data included age at the time of
presentation for cancer, and the pathological findings
included tumor size, axillary lymph node status, tumor
histological grade, and ER status. All pathological speci-
mens were reviewed by breast pathologists at NCKUH.Tumor size was measured using pathological reports
from NCKUH. The Scarff-Bloom-Richardson (SBR) sys-
tem was used for tumor grading and was based on the
following morphological features: nuclear pleomorphism
of tumor cells, degree of tumor tubule formation, and
tumor mitotic activity. To determine the ER status,
immunohistochemistry was performed on formalin-
fixed, paraffin-embedded breast cancer tissue samples
from the patients. Positive ER status was defined as nu-
clear staining > 1%. Immunohistochemistry was per-
formed using anti-ER (clone 6 F11, Ventana Medical
Systems, Strasbourg, France). Postoperative adjuvant
chemotherapy was performed according to the NCCN
and St. Gallen guidelines.
Postoperative adjuvant chemotherapy was performed
according to NCCN and St. Gallen guidelines. Between
the period 1992 to 1995, CMF regimen was used as
standard chemotherapy (cyclophosphamide 500 mg/m2,
methotrexate 50 mg/m2 and 5-FU 500 mg/m2). Since
1996, FEC regimen (5-FU 500 mg/m2, epirubicin
100 mg/m2 and cyclophosphamide 500 mg/m2) was
given in the majority of patients. Since 1998, for high
risk patients, TEC regimen (Taxotere 75 mg/m2, epirubi-
cin 75 mg/m2 and cyclophosphamide 500 mg/m2) was
performed.
χ2 and two-sample independent t tests were used to
compare variables between the two subgroups. Data for
demographic and tumor characteristics for each patient,
such as age, ER status, grade, tumor size, lymph node
status, and treatment modalities (chemotherapy or/and
hormone therapy) were entered into the Adjuvant! On-
line program (version 8.0), which produced a 10-year
predicted probability for death due to breast cancer. For
the comorbidity item “average for age” was imputed for
all patients. The Hosmer–Lemeshow test was used to as-
sess whether the predicted probabilities matched the
observed probabilities in subgroups of the patient popu-
lation [13]. The difference in the number of categories
reflects the different subgroup sizes. P values < 0.05 were
considered significant. The observed probability was
regressed on the predicted probability, and R2 was calcu-
lated to measure the goodness of fit of the linear regres-
sion line. All statistical analyses were performed with
SPSS 17.0 software.
Results
The patients’ characteristics and the distribution of the
whole patient cohort is described in Table 1. The mean
10-year predicted death probability in 559 patients was
19.44%, and the observed death probability was 15.56%
(p < 0.001). The predicted event rate evaluated using the
Adjuvant! Online formula significantly overestimated the
real event rate in the patients in Taiwan. We used the
linear regression model to adjust for the difference
Table 1 Patient characteristics in the whole cohort
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culating the predicted probability using the Adjuvant!
Online formula as the first step, inserting the predicted
value into the regression formula, and then estimating
the observed probability. Compared with the predicted
probability, the estimated observed probability was
closer to the real probability. The calculated R2 was
0.843, showing excellent fit of the regression model.
However, in our study, the model was overoptimistic
in the high risk patients. We categorized the patients
into low- and high-risk subgroups. Patients with all of
following prognostic factors were classified as low-risk:
aged ≥ 35 years and had a tumor size ≤ 2 cm, negative
lymph node status, positive ER/PR receptor status, and
tumor grade I. The patients with any one of the follow-
ing prognostic factors will be classified as high-risk:
aged < 35 years or had a tumor size > 2 cm or positive
lymph node status or tumor grade II or III or negative
ER/PR receptor status. Comparison between the low-and high-risk groups showed significant differences in
tumor grade, tumor size, and lymph node distribution
(p < 0.0001), which justified the division of the patients
into the two subgroups. The mean age did not differ sig-
nificantly between the two groups (p= 0.056). (Table 2).
In 78 low-risk patients, the mean predicted death
probability was 3.69%, which did not differ significantly
from the 3.85% observed death probability (ratio of pre-
dicted/observed risk = 0.96; p= 0.099). The Adjuvant!
Online probability accurately predicted the outcomes of
patients in the low-risk group. However, the difference
between predicted and observed death probabilities was
significant in the 481 high-risk patients. A linear regres-
sion model was also constructed to adjust for the differ-
ence between the predicted and observed probabilities in
the high-risk subgroup. The calculated R2 was 0.86,
showing excellent fit of the regression model (Figure 1).
The Adjuvant! Online model showed an overestimation
of breast cancer-specific survival in Taiwanese high risk
breast cancer patients (ratio of predicted/observed risk
= 1.26; p= 0.016) (Figure 2).
The rate of loss to follow-up was 14.26% because some
patients were lost of follow-up after 5 years hormonal
treatment. These patients were excluded from our data
analysis, and our more conservative data analysis
method might have overestimated the death probability.
Discussion
Adjuvant treatment for postoperative early breast cancer
patients remains a great challenge for physicians and
patients who must consider both the risks and benefits
of treatment, possible comorbidities, and especially the
desire to maintain quality of life. Several tools to support
decisions have been developed [5,7,8,14,15]. One such
tool, Adjuvant! Online, is a computerized, Web-based
program that predicts recurrence and mortality risk and
the benefit of adjuvant treatment in early breast cancer
patients [10]. The program is based on the database
from the US SEER tumor registry database. The SEER
tumor registry collected information from about 10% of
all breast cancer cases in the USA. The database used
for Adjuvant! Online included information such as the
patients’ demographics and tumor characteristics (tumor
size, the number of positive nodes, tumor grade), and
survival in postoperative breast cancer patients aged 20
to 79 years between 1988 and 1992 [11]. After entering
these data, the program calculated the annual breast
cancer mortality rates and produced data for comparison
with the database from the SEER tumor registry. These
data were used to predict the 10-year survival. Adjuvant!
Online can be used to provide recommendations for ad-
juvant systemic therapy after considering the estimated
10-year overall survival (OS), breast cancer-specific sur-
vival (BCSS), and event-free survival (EFS) However, the







Age, years 51.7 (11.0%) 49.1 (11.1) 0.056
ER < 0.0001
Negative 0 192 (39.9)
Positive 78 (100%) 279 (58.0)
Unknown 0 10 (2.1)
Grade < 0.0001
I 78 (100%) 52 (10.8)
II 0 204 (42.4)
III 0 105 (21.8)
Unknown 0 120 (24.9)
Tumor Size < 0.0001
T1 78 (100%) 183 (38.0)
T2 0 259 (53.8)
T3 0 39 (8.1)
Node < 0.0001
N0 78 (100%) 245 (50.9)
N1 0 135 (28.1)
N2 0 50 (10.4)





Yes 76 (97.4) 400 (83.2)
No 2 (2.6) 81 (16.8)
Chemotherapy < 0.0001
Yes 31 (39.7) 350 (72.8)
No 45 (57.7) 104 (21.6)
Less than expected cycles 2 (2.6) 27 (5.6)
Observed probability 3.85% 17.46%
Predicted probability 3.69% 21.99%
Figure 1 Predicted versus observed outcome in the high-risk
breast cancer patients in our patient population.
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populations raises questions about the combination of
prognostic factors and accuracy of patients’ characteris-
tics. Our goal was to determine the accuracy of the pro-
gram applied to an Asian population and, if the program
is accurate, which subgroup should be included.
The tool has been validated and used by oncologists in
different countries including Canada, Germany, Holland,
and the United Kingdom (UK) [12,16-19]. In an analysis
of 4083 early breast cancer patients in Canada, Olivotto
et al. showed that the overall predicted and observed 10-
year outcomes were within 2% for OS, BCSS, and EFS
[12]. The Adjuvant! Online program was also validated
in small cohorts of patients in Germany [19]. The
increased use of the program by physicians and thepositive results in Western countries prompted us to
analyze the accuracy of the program in an Asian
population.
In the present study, the difference between the pre-
dicted and observed outcomes in the low-risk cohort
was about 1%. We conclude that Adjuvant! Online is an
accurate tool for predicting the outcome in low-risk
breast cancer patients in the Taiwanese population. By
contrast, we observed a large discrepancy between our
prediction and that of Adjuvant! Online in the high-risk
population. That is, Adjuvant! Online underestimated
the mortality risk in the high-risk subgroup of Taiwanese
breast cancer patients. Considering this discrepancy, we
suggest that a correction factor of 1.259 might be justi-
fied for high-risk patients. Variations in the program val-
idation may differ between countries and ethnic factors
are known to be determining factors that can influence
the decision about and outcomes of adjuvant treatment.
The program should be validated in different countries
and ethnic groups before wider application of these data.
Campbell et al. showed that the recommendations for
adjuvant treatment made by a UK-based multidisciplin-
ary team using Adjuvant! Online would improve deci-
sion making in only a minority (2.5%) of patients [16].
Our results are similar to those of Campbell et al. In a
cohort of 1065 British early breast cancer patients,
Campbell et al. found that Adjuvant! Online significantly
overestimated OS (5.54%, p < 0.001), BCSS (4.53%,
p < 0.001), and EFS (3.51%, p= 0.001). They concluded
that overestimation of BCSS implies that Adjuvant! On-
line underestimates breast cancer mortality for women
in the UK. One possible reason for this difference may
be that the breast cancer mortality rate is lower in the
USA than in the UK.
A Dutch validation study of 5380 breast cancer
patients showed no significant differences between the
Figure 2 Ratio of predicted risk to observed risk between the
low-risk and high-risk subgroups. Pred: predicted risk, obs:
observed risk. *: the difference between predicted and observed risk
was not significant (p = 0.099). The Adjuvant! Online model showed
a good discriminative performance in the low risk patients. +: the
difference between predicted and observed risk was significant
(p = 0.016). The Adjuvant! Online model showed an overestimation
of observed 10-year breast cancer-specific survival in the high risk
patients.
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Adjuvant! Online-predicted OS and BCSS (p= 0.87 and
p= 0.18, respectively) [20]. However, in the subgroup
with patients aged < 40 years, Adjuvant! Online overesti-
mated the predicted OS and BCSS (4.2%, p= 0.04 and
4.7%, p= 0.01, respectively). In the patient subgroup
older than 69 years, Adjuvant! Online overestimated the
predicted OS (3.4%, p= 0.05). Finally, the program
underestimated predicted BCSS in the patient subgroup
with 1–3 lymph node metastases (3.1%, p= 0.002). Our
data are consistent with these earlier findings in that we
found that Adjuvant! Online predicted BCSS accurately
in some patient subgroup.
Compared with other studies that validated the accur-
acy and performance of Adjuvant! Online, our study
might be considered to have had a small sample size.
However, one advantage in our study is the low propor-
tion of missing data. Data for tumor size, lymph node sta-
tus, ER status, and tumor grade were collected routinely
and rechecked by a clinician and data manager, and our
missing data rate was around 25%. Our missing data rate
is similar to the publication from Bhoo-Pathy et al. (25%)
[21]. In the study by Mook et al., 3104 of 5380 patients
(58%) had data missing for ER status or tumor grade.
However, they concluded that including the patients with
incomplete data did not influence the prediction of out-
comes. The program can also predict disease outcome
without information about ER status. By contrast, Adju-
vant! Online tend to underestimate the BCSS in ER-
negative breast cancer patients. Mook et al. concludedthat this result was observed in patients undergoing hor-
monal treatment [20]. Another limitation of our study is
the adjuvant treatment modalities. The period of data re-
cruitment for this study was from 1992 to 2001. Accord-
ing to the NCCN guidelines and policy of Taiwan national
health insurance, standard adjuvant chemotherapy com-
prised CMF (cyclophosphamide, methotrexate, and fluor-
ouracil) or an anthracycline-based regimen, and standard
adjuvant endocrine therapy comprised tamoxifen for HR-
positive patients. However, the treatment varies between
countries, especially in relation to different national pol-
icies for the use of treatments, such as taxane-containing
regimen chemotherapy or aromatase inhibitors.
Conclusions
This validation study of Adjuvant! Online applied to a
university hospital-based cohort of Taiwanese breast
cancer patients showed that the calculated predictions
by Adjuvant! Online matched the observed outcomes
and that the predictions are suitable when applied to
low-risk, early breast cancer patients. We agree that
Adjuvant! Online is a useful tool for doctors and
patients, but it should be used only by those aware of its
limitations, as advised in the program’s instructions and
as reported elsewhere.
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